Between December 8 and December 10, 2025, SNY faced a series of analyst rating adjustments that tempered investor sentiment.

Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on ...

Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysemaAdditional orphan designation ...

Sanofi (EURONEXT: SAN) announced Wednesday that its investigational therapy, efdoralprin alfa, has received orphan drug ...

Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

Sanofi is to take on Boehringer Ingelheim's consumer health division in exchange for its animal health business Merial – the latest in a trend for multi-billion swaps in big pharma. The deal will see ...

Two large deals and an acquisition, all totaling about $4.64 billion, are helping close out a strong year. Yarrow Bioscience Inc. cut a potentially $1.36 billion deal with Shanghai Scizeng Medical ...

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

"Sanofi signs pair of billion-dollar biotech deals to bolster pipeline" was originally created and published by ...

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...

ADEL Inc., a biopharma company, has entered into an exclusive worldwide license agreement with Sanofi for the development and ...

South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to ...